Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
|
|
- Domenic Bryan
- 6 years ago
- Views:
Transcription
1 GASTROENTEROLOGY 2012;143: Sustained Responses and Loss of HBsAg in HBeAg-Negative atients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir STEHANOS J. HADZIYANNIS,*, VASSILIOS SEVASTIANOS,* IRENE RATI,* DIMITRIOS VASSILOOULOS, and EMILIA HADZIYANNIS *Department of Medicine and Hepatology, Henry Dunant Hospital, 2nd Academic Department of Medicine, Hippokration Hospital, and the Molecular Biology Laboratory of the Liver Unit at the Evgenidion Hospital, National and Kapodistrian University of Athens, Athens, Greece BACKGROUND & AIMS: Little is known about the biochemical and virological effects of stopping long-term nucleos(t)ide analogue therapy for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). METHODS: We performed a cohort observational study, following 33 HBeAg-negative patients with CHB, undetectable serum HBV DNA, and normal levels of aminotransferases after long-term (4 or 5 years) treatment with adefovir dipivoxil (ADV). All patients were followed for 5.5 years; follow-up visits included measurements of serum alanine aminotransferase (ALT), hepatitis B surface antigen (HBsAg), and HBV DNA monthly for the first 6 months and every 3 6 months thereafter. Various factors were measured at baseline, the end of treatment (EOT), and following treatment to identify those associated with clearance of HBsAg. RESULTS: During the first few months of the postdiscontinuation period, all patients experienced virological and 25 (76%) had biochemical relapse. During the follow-up period, 18 patients (55%) who had discontinued antiviral therapy achieved sustained response (HBV DNA level 2000 IU/L, persistently normal level of ALT). Among these, 13 (72%) cleared HBsAg. Fifteen patients (45%) with virological and/or biochemical relapse were re-treated with oral antiviral agents (11 during the first 18 months and 4 after the third year), without evidence of liver decompensation; only 1 lost HBsAg (6%). Higher pretreatment and EOT levels of ALT, no previous treatment with interferon, and lower level of HBsAg at the EOT were significantly associated with HBsAg clearance based on multivariate analysis. CONCLUSIONS: In HBeAg-negative patients with CHB, it is safe and effective to discontinue ADV therapy after 4 or 5 years; 55% of patients have sustained responses, and 39% of patients lose HBsAg. Keywords: rospective Clinical Trial; Replication Suppression; Liver Disease. Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is currently the predominant type of CHB in Europe, the Mediterranean basin, and many other geographical regions of the world. 1 5 Although it represents an immune active phase in the course of chronic hepatitis B virus (HBV) infection, 6,7 the host immune mechanisms not only fail to eliminate the virus or suppress its replication, but they also lead to progressive immune-mediated chronic liver damage. 8 Ideally, treatment of CHB should be aiming at HBV elimination, but because this is not a goal easily achievable with currently available therapies, a generally accepted treatment approach is potent and durable suppression of HBV replication, which could lead to prevention of cirrhosis and hepatocellular carcinoma (HCC). 9 However, in HBeAgnegative CHB, discontinuation of finite treatments of up to 3-year duration with oral nucleos(t)ide analogues (NUCs) is followed by virological and biochemical relapses in the majority of patients and the benefits gained by therapy are lost Therefore, current treatment guidelines 4,19 for HBeAg-negative CHB recommend longterm/indefinite oral antiviral therapy without development of HBV resistance. 2,20 What would be the outcome of both chronic HBV infection itself and the underlying liver disease if such long-term therapies with NUCs were discontinued? This remains hitherto unknown because such a treatment strategy has not been thus far attempted. On the other hand, long-term follow-up data from cohorts of HBeAgnegative patients treated with conventional or pegylated interferons have shown that sustained biochemical and virological remissions followed by loss of hepatitis B surface antigen (HBsAg) do occur in a good proportion of patients with HBeAg-negative CHB after stopping such treatment In this prospective long-term follow-up study, the rate of biochemical and virological responses, including HBsAg loss, was assessed in a cohort of patients with HBeAg-negative CHB after discontinuation of effective long-term treatment (4 or 5 years) with adefovir dipivoxil (ADV). 26,27 atients and Methods Study Design This was a prospective, cohort, observational study initiated immediately after stopping a 192- or 240-week ADV treatment regimen in patients with HBeAg-negative CHB included in a randomized placebo-controlled trial (GS ), the Abbreviations used in this paper: ADV, adefovir dipivoxil; CHB, chronic hepatitis B; EOT, end of treatment; NUC, nucleos(t)ide analogue; OR, odds ratio; CR, polymerase chain reaction; SR, sustained response; ULN, upper limit of normal by the AGA Institute /$
2 630 HADZIYANNIS ET AL GASTROENTEROLOGY Vol. 143, No. 3 Figure 1. Flow chart showing the disposition of patients in the different cohorts of the open-label ADV study. results of which have already been published in detail. 14,26,27 The original study design consisted of an initial double-blinded phase of 96 weeks, followed by an open-label, long-term safety and efficacy period of 144 weeks. In this international prospective trial, 185 patients were enrolled initially in the year 2000 at 32 sites. 26 atients were randomly assigned to receive 10 mg ADV (n 123) or placebo (n 62). At week 49, 119 patients initially treated with ADV were randomized either to continue treatment (ADV-ADV group) or switch to placebo (ADV-placebo group) and patients initially given placebo were switched to ADV (placebo-adv group), all in a double-blind manner. From week 96 and on, all patients in the GS study continued longterm ADV therapy. Treatment ended at study week 240. Thus, patients in the ADV-ADV group (n 70) received treatment for 240 weeks (5 years) and those in the placebo-adv group (n 55) for up to 192 weeks (4 years); they are herein also referred as cohorts A and B, respectively. At week 240, a liver biopsy was performed for the patients of both cohorts according to the protocol and ADV treatment was terminated. atients Forty-seven patients with HBeAg-negative CHB from Athens, Greece, were randomly allocated to one of the 2 cohorts of long-term ADV treatment (ADV-ADV, n 27; placebo-adv, n 20). From the third year of the long-term ADV trial and on, all patients were treated and followed up in the Liver Unit of the Henry Dunant Hospital of Red Cross of Athens (Figure 1 and Table 1). Ten patients (21%) experienced virological and biochemical breakthrough during ADV therapy and had been entered in rescue protocols, while 37 (79%) achieved longterm HBV suppression (undetectable serum HBV DNA) that was maintained up to the end of treatment (EOT) without development of genotypic HBV resistance. Four of the 37 patients did not agree to stop therapy and continued to receive ADV that was already commercially available. All 33 remaining patients accepted treatment discontinuation and signed an informed consent that also included acceptance of the follow-up protocol of long-term observation and possible re-treatment. Their overall characteristics are depicted in Table 1. There was no significant difference by the Mann Whitney test in the characteristics of the patients in the 2 cohorts of long-term ADV treatment. Follow-up rotocol atients were evaluated every month for the first 6 months and every 3 6 months (or more frequently if clinically indicated) during the posttreatment follow-up period. A complete physical examination and laboratory assessment including Table 1. Number and Characteristics of all atients in the ADV GS Study of 5- or 4-Year Duration and Those From Athens Who Gave Informed Consent for Discontinuation of Treatment and Long-term Follow-up All patients in the GS study Athens cohort n Consent for ADV discontinuation EOT virologic response, n (%) 84 (67) 37 (79) 33 Age (y), median (range) 47 (18 65) 53 (29 69) 52 (29 69) Male/female 103/22 38/9 27/6 Baseline ALT s (U/L), median (range) 99 (24 742) 109 (44 457) 100 (44 408) Serum HBV DNA (log 10 copies/ml), median (range) 7.12 ( ) 7.27 ( ) 7.15 ( ) Knodell necroinflammation score, median (range) 7 (2 17) 7 (4 17) 7 (4 17) Ishak fibrosis score, median (range) 2 (1 4) 3 (1 4) 3 (1 4) 5/4-year treatment duration, n 70/55 27/20 22/11 HBV genotype All D
3 September 2012 SUSTAINED AND HBsAg LOSS IN CHB RESONSES 631 alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase, -glutamyl transpeptidase, albumin, globulin, prothrombin time, blood cell count, blood urea nitrogen, creatinine, lipid profile, and glucose were performed in each visit. -Fetoprotein and serologic markers of HBV infection (including a semiquantitative assay of antibody to hepatitis B core antigen [anti-hbc] immunoglobulin M) were repeatedly tested. Ultrasonography of the upper abdomen and power Doppler of the Haller s tripod were performed every 6 months. Laboratory Methods Virological, serological, and biochemical assays were performed by methods described in previous publications of the GS study. 14,27 Quantification of serum HBsAg was performed by the Architect analyzer (chemiluminescent immunoassay, Abbott Laboratories, Abbott ark, Illinois, cutoff, 0.04 IU/mL). A Roche real-time HBV DNA polymerase chain reaction (CR) assay (Cobas TaqMan) with a lower limit of quantitation of 169 copies/ml or 29 IU/mL was used during the last year of the GS study, at the EOT (as described in detail in previous publications of the GS trial), and during the first 4 months of the posttreatment follow-up. 14,27 All available subsequent sera that were initially tested by an in-house real-time CR (detection limit, 1000 copies/ml or 200 IU/mL) were retested by the current automated Cobas Amplirep TaqMan assay (Roche Molecular Systems Inc, leasanton CA) with a lower limit of quantitation of 20 IU/mL. Definitions of Events The events of interest were defined as follows during follow-up. EOT virological response. Undetectable serum HBV DNA (by Cobas TaqMan Real Time CR; detection limit, 29 IU/mL). Virological remission. Decline of serum HBV DNA levels to nondetectability or 2000 IU/mL (by a real-time CR assay with a detection limit of 200 IU/mL as standardized on the basis of the Cobas TaqMan real-time CR test). Virological relapse. Increase in HBV DNA level 2000 IU/mL or increase by 1 log 10 from nadir in 2 consecutive measurements at least 3 months apart. Sustained response. ersistently not detectable HBV DNA or 2000 IU/mL combined with persistently normal ALT s (upper limit of normal [ULN], 40 U/L) following posttreatment month 6 sustained to the end of follow-up. Biochemical relapse. Increase in ALT level 1.2 times ULN. Hepatitis flare. Increase in ALT level 10 times ULN. Criteria for Re-treatment of atients Experiencing a Relapse After Discontinuation of Long-term ADV Therapy After discontinuation of therapy, re-treatment with ADV or other NUCs was offered to patients in biochemical and virological relapse with ALT level 2.5 times ULN persisting for more than 4 months without any spontaneous decline toward normal as well as to patients with posttreatment ALT flares exceeding 10-fold times ULN that persisted for more than 2 months in consecutive assays. For safety reasons, depending on the clinical and laboratory findings, patients were subjected to repeated clinical assessment and to laboratory testing with additional examinations scheduled on an individual basis. Figure 2. The number of patients who experienced a relapse and received antiviral therapy (relapsers) or lost HBsAg among the remaining patients during follow-up. Statistical Analysis Data entry and statistical analysis were performed with the statistical package IBM SSS Statistics (version 19.0; SSS Inc, Chicago, IL). In all cases, tests of significance were 2 tailed with a level at.05. Corrected 2 or 2-tailed Fisher exact test and t test or Mann Whitney test were used for qualitative and quantitative data when appropriate. Logistic regression models were used for multivariate analysis, and the Kaplan Meier method was used to estimate the rates of HBsAg loss and the log-rank as a test for significance. Quantitative variables that were normally distributed were expressed as mean s SD, and those non-normally distributed were expressed as median s (range). Multivariate analysis (backward stepwise logistic regression analysis) of variables with.10 at univariate analysis was performed to identify independent factors associated with sustained response (SR) and HBsAg loss. The study was conducted in compliance with the 1975 Declaration of Helsinki and approved by local regulatory bodies. Authors contributed to the design, execution, analysis, or interpretation of the study, and each author contributed to the writing and approved the final manuscript. Results atients Outcome All 33 patients who had discontinued ADV (Figure 1) completed a 5.5-year period of posttreatment observation, with a median duration of 69 months (range, months). Their baseline characteristics in comparison to the initial cohorts of the GS study are shown in Table 1. All patients are alive and in excellent general condition, and none of them have developed cirrhosis or HCC. Eighteen patients (55%) achieved sustained biochemical and virological remission with 13 of them also clearing HBsAg (39%), thus resulting in a 5.5-year rate of HBsAg clearance of 72% among sustained biochemical/ virological responders who stopped ADV treatment and of 35% among all 37 patients from Athens with EOT response (Figure 2). atients with HBsAg loss have hitherto continued to be followed up regularly at 6-month intervals. None of them have reversed to HBsAg positivity, and 9 (69%) have stably seroconverted to antibody to HBsAg. It is noteworthy that none of the 4 individuals who did not consent to stop therapy have hitherto experienced HBsAg loss, while one of them has developed
4 632 HADZIYANNIS ET AL GASTROENTEROLOGY Vol. 143, No. 3 Figure 3. The course of (A and B) ALT and (C and D) HBV DNA levels during the first 12 months off treatment in patients with biochemical relapse (n 25) who either resumed antiviral therapy (n 15; A and C) or remained without antiviral therapy (n 10; B and D). For patients who resumed antiviral treatment during the first year (n 9), ALT and HBV DNA s are shown until the onset of therapy (A and C). In E, the course of HBV DNA in the 8 patients who did not receive antiviral therapy and did not show biochemical relapse is also shown. Undetectable HBV DNA s are assigned a of 1. HCC. HBsAg loss has occurred in 8 of 22 (36.4%) and 5 of 11 (45.5%) patients in cohorts A and B, respectively ( NS). Virological and Biochemical rofiles During Follow-up Serum HBV DNA was negative at EOT in all patients (N 33) but became again detectable in the first month after treatment discontinuation. In the majority of patients (29/33 [88%]), posttreatment serum HBV DNA levels peaked either in the first (n 22) or second posttreatment month (n 7). The posttreatment reappearance of serum HBV DNA was also observed in low levels in 3 patients with hardly detectable HBsAg at EOT ( 5.23 IU/mL), but HBV DNA became again undetectable at month 2 and has remained persistently negative thereafter up to the end of follow-up. In 25 of the 33 patients (76%), HBV reactivation was associated with transient or persisting biochemical relapse (Figure 3). The increase in ALT level occurred either concomitantly (11/25 [44%]) with the reappearance of HBV DNA or 1 2 months later. The duration of the biochemical relapse was transient in most of the patients and by month 9 of follow-up, ALT s had declined to normal levels. In Figure 3, the individual serial ALT and HBV DNA titers among patients with (n 25) or without (n 8) biochemical relapse who were either re-treated (n 15; Figure 3A and C) or not (n 10, Figure 3B and D) are shown. The change in HBV DNA titers is also depicted for the 8 untreated patients who did not show biochemical relapse (Figure 3E). At the end of the first year, 15 patients who did not receive re-treatment with antivirals were already in SR and their number increased to 16 at the end of year 2, while beyond year 3 until the end of follow-up, 18 patients remained in SR (55%; Figure 2 and Supplementary Figure 1). The rate of HBsAg loss among those untreated patients with SR gradually increased from 20% (3/15) in year 1 to 37.5% in year 2 (6/16), 44% in year 3 (8/18), 50% in year 4 (9/18), 55.5% in year 5 (10/18), and 72% at the end of follow-up (13/18; Figure 2 and Supplementary Figure 1). Among the 5 patients with SR who did not lose
5 September 2012 SUSTAINED AND HBsAg LOSS IN CHB RESONSES 633 HBsAg, 3 had undetectable HBV DNA at the end of follow-up and 2 had low HBV DNA levels ( 2000 IU/mL; Supplementary Figure 1). Treatment of Relapsing atients During follow-up, 15 of the 33 patients (45%) have experienced biochemical and virological relapse (Figures 2 and 3) and have received salvage therapy either with lamivudine or ADV. Six patients during the early follow-up period (asymptomatic, without any laboratory evidence of hepatic decompensation) were re-treated with NUCs immediately after the first increase in ALT level at their own request, without waiting for the results of retesting (as required by the protocol). All of these early treated patients were considered relapsers, and none of them lost HBsAg during long-term follow-up. Nine more patients displayed persistent virological and biochemical relapse during the following 5 years of follow-up (Figure 2). Among the 15 relapsing patients who were re-treated with NUCs for indefinite duration, only one has hitherto achieved HBsAg loss (6%). redictors of HBsAg Loss The following variables were assessed as possible determinants/predictors of HBsAg loss: age, sex, ALT (pretreatment, EOT, peak ALT during the first posttreatment year), previous interferon treatment, serum HBV DNA levels (before ADV treatment), duration of HBV DNA detectability during ADV treatment, liver necroinflammation and fibrosis (pretreatment, EOT), HBsAg (EOT, not enough sera were available for HBsAg titration at baseline), timing of ALT and HBV DNA peak during the first posttreatment year, and duration of ADV treatment (4 or 5 years). These different pretreatment, EOT, and posttreatment variables were examined as potential predictors of HBsAg loss either among the total patient population (N 33 Table 2) or among non re-treated patients only (n 18) (data not shown). Among all patients who discontinued long-term effective ADV treatment (N 33), lower pretreatment HBV DNA levels (odds ratio [OR], 0.99;.04), higher ALT level at EOT (OR, 1.18;.007), lower HBsAg titer at EOT (OR, 1;.02), no previous interferon treatment (OR, 0.07;.002), and no re-treatment with antivirals (OR, 0.03;.002) were associated by univariate analysis with HBsAg loss (Table 2). It should be mentioned that all patients who lost HBsAg were male (14/14) compared with those who remained HBsAg positive (13/19;.03 by Fisher exact test), although this could not be tested by univariate analysis. Using multivariate analysis at the different time points of follow-up (pretreatment, EOT, first posttreatment year), higher pretreatment (OR, 1.02;.027) and EOT (OR, 1.29;.019) ALT levels, lower HBsAg levels at EOT (OR, 0.99;.033), and no re-treatment with antivirals after discontinuation of ADV (OR, 0.027;.002) were associated with HBsAg loss. Using a model in which the most significant variables by multivariate analysis at the different time points were included, none of these variables showed a statistically significant association with HBsAg loss (Table 2). The same analysis was performed in the 18 patients who did not resume antiviral therapy during posttreatment follow up (data not shown). By univariate and multivariate analysis, only ALT level at EOT (OR, 1.31; 95% CI, ;.035) was associated with HBsAg loss. It should be mentioned that none of the patients who remained HBsAg positive exhibited biochemical relapse during posttreatment follow-up (0/5), compared with 77% of those who lost HBsAg (10/13;.007 by Fisher exact test; Supplementary Figure 1), while all patients who lost HBsAg were male (13/13 vs 3/5;.06 by Fisher exact test). These 2 variables could not be tested by univariate analysis. HBsAg Titers HBsAg levels, measured at the end of long-term ADV therapy, were lower in patients with SR who finally cleared HBsAg (mean SD, ; median/range, 161/ IU/mL) compared with relapsers (mean SD, ; median/range, 4837/983 11,543 IU/ ml;.002; Figure 4) and patients with SR who did not clear HBsAg (mean SD, ; median/range, 5242/124 11,233 IU/mL), although the difference did not reach statistical significance with the latter group (.07; Figure 4). In Supplementary Figure 1, the individual changes in HBsAg titers among non re-treated patients (n 18) are shown both for those who remained HBsAg positive (n 5; Supplementary Figure 1A, C and E) or lost HBsAg (n 13; Supplementary Figure 1B, D and F). Discussion Stopping courses of up to 3-year duration of antiviral treatment with NUCs in HBeAg-negative CHB is followed by biochemical relapses in the vast majority of patients, induced by resumed replicative activity of HBV and reflected by increases in ALT and serum HBV DNA levels, respectively This was also the case in the mother placebo-controlled GS study with the ADV-placebo group, in which patients were left untreated despite virological and biochemical relapses, without any significant adverse events. 14 Nevertheless, for safety reasons, stringent criteria were applied in the present study regarding the management of relapses after stopping long-term treatment with ADV, even though all included patients had compensated liver disease, normal liver function test results, and significant improvement in liver necroinflammation and fibrosis. 27 Despite the fact that all 33 patients who were followed up were in long-term remission under ADV treatment, HBV DNA became again detectable in serum in all of them soon after treatment was discontinued. However, the increase in serum HBV DNA level was transient and rather low. These findings are not surprising in view of our previous observations showing that HBV covalently
6 Table 2. Comparison Between atients Without (n 19) and With HBsAg Loss (n 14) Among the Whole atient opulation (N 33) Characteristic No HBsAg loss (n 19) HBsAg loss (n 14) Univariate analysis Multivariate analysis a Multivariate analysis (.1) b Multivariate analysis c OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Before/during ADV treatment Age ( ) ( ).151 revious interferon treatment 15/4 3/ ( ) ( ) ( ) ( ).084 (yes/no) ALT (U/L) ( ) ( ) ( ) ( ).066 HBV DNA (IU/mL), median 6.38 ( ) 5.93 ( ) ( ) ( ) ( ) ( ).094 (range) Liver necroinflammation ( ) ( ).201 (Knodell) d Liver fibrosis (Knodell) d ( ) ( ) ( ) ( ).087 Duration of ADV therapy (4/5 6/13 6/ ( ) ( ).165 years) Duration of HBV DNA ( ) ( ).122 undetectability (mo) End of ADV treatment (EOT) ALT (U/L) ( ) ( ) ( ).019 HBsAg titer (IU/mL) ( ) ( ) ( ).040 Liver necroinflammation ( ) ( ).178 (Ishak) e Liver fibrosis (Ishak) e ( ) ( ).449 ost-adv treatment follow-up eak ALT after stopping ADV ( ) ( ).346 (first year) Timing of peak ALT (mo) ( ) ( ).432 eak HBV DNA (IU/mL), 5.15 ( ) 4.67 ( ) ( ) ( ).185 median (range) Timing of peak HBV DNA ( ) ( ).123 (mo) Re-treatment after stopping ADV (yes/no) 14/5 1/ ( ) ( ) ( ) ( ).093 NOTE. A number of variables before, during, at the end of, and after ADV treatment were compared between patients who finally achieved HBsAg loss and those who did not in the whole population of patients (N 33). Normally distributed variables are presented as mean SD, and non-normally distributed variables are presented as median (range). Qualitative data were compared using 2-tailed Fisher exact test and quantitative data using t test or Mann Whitney test (as appropriate), and results are shown in the third column. Results of univariate and multivariate analysis were also performed and s and ORs with 95% confidence intervals (95% CIs) are depicted (in bold;.05). a Results of multivariate logistic regression analysis of HBsAg loss using all available variables for each of the 3 periods (before/during ADV treatment, EOT, and after ADV treatment [first year]) are shown. b Results of multivariate logistic regression analysis of HBsAg loss using only variables with.1 at the multivariate analysis for each of the 3 periods as in a. c Results of multivariate logistic regression analysis of HBsAg loss including all variables with.1. Here all available variables from all periods were taken into account. d Liver biopsy data available for 31 patients before ADV treatment. e Data available for 24 patients at EOT. 634 HADZIYANNIS ET AL GASTROENTEROLOGY Vol. 143, No. 3
7 September 2012 SUSTAINED AND HBsAg LOSS IN CHB RESONSES 635 Figure 4. EOT HBsAg levels in patients with SR and HBsAg loss (n 13) vs patients with virological and biochemical relapse (n 15;.002) or patients with SR without HBsAg loss (n 5;.07). SR indicates persistently not detectable HBV DNA or 2000 IU/mL combined with persistently normal ALT level following posttreatment month 6 sustained until the end of follow-up. closed circular DNA in the liver, although greatly reduced, still remain detectable despite effective long-term suppression of HBV replication, 28 while the same can be observed even in patients who clear HBsAg. 29 The spontaneous decrease of posttreatment serum HBV DNA levels to low ( 200 IU/mL) or nondetectable levels combined with long-term biochemical remission and subsequent loss of HBsAg indicate that the host immune mechanisms that had been modulated during the long period of HBV suppression by ADV treatment reacted effectively to the resumed HBV replication, eventually clearing those hepatocytes that had started to re-express HBV proteins. Such an immune-mediated clearance of HBV-infected hepatocytes represents the main mechanism of CHB remission and HBsAg loss following interferon alfa therapy. 19,24,30 However, for such an immune clearance to be mounted, the immune system needs not only to become modulated but also to be re-exposed to the antigens of the replicating virus. HBsAg loss is considered the closest to cure outcome of chronic HBV infection and the golden goal of current therapies, particularly in difficult-to-treat patients with HBeAg-negative CHB. 4,19,24 Therefore, our results from the multivariate logistic regression analysis showing that lower HBsAg levels at EOT were associated with a higher probability of future HBsAg loss indicate that low HBsAg levels at EOT could predict a subsequent HBsAg loss. Although a specific cutoff point with a high negative or positive predictive for HBsAg loss could not be established (probably due to the small number of patients), this observation is of practical clinical relevance and needs to be confirmed in future large-scale studies. Among the other pretreatment variables studied, no previous interferon treatment, higher ALT levels, and lower HBV DNA levels were also associated with HBsAg loss in our multivariate logistic regression analysis. Similarly, among the EOT variables, higher ALT levels were associated with HBsAg loss, along with the HBsAg levels. However, the mean ALT s in those who lost HBsAg compared with those who did not were within the normal range. As expected, no re-treatment with antivirals after discontinuation of ADV was the strongest predictor of HBsAg loss among the whole patient population. Among the population of non re-treated patients, only a higher ALT level at EOT was associated with HBsAg loss in the multivariate logistic regression analysis. Collectively, these findings suggest that among patients whose immune system is able to recognize and lyse HBV-infected hepatocytes (probably reflected by a higher ALT level), a significant proportion can eventually achieve HBsAg clearance. Ongoing studies assessing viral expression (total HBV DNA, covalently closed circular DNA, RNA transcripts, HBsAg, hepatitis B core antigen) in the liver as well as host immune responses (serum immunoglobulin M anti-hbc level and type of liver inflammation) during the posttreatment period could provide additional information regarding the pathophysiology and potential predictors of HBsAg clearance in this population. Due to its surprisingly good results, this long-nuc treatment/discontinuation study actually represents an emerging new treatment paradigm that could be carefully applied to patients with HBeAg-negative CHB who have compensated liver disease but not to patients with cirrhosis or advanced liver fibrosis who, in case of severe posttreatment biochemical relapse, may be at risk for development of liver failure. A limitation of this study is the small number of included patients. However, the vast majority of patients from our center who participated in the international long-term mother study (33/37) gave informed consent for stopping therapy and all of them have been followed up for approximately 6 years. Another potential limitation could be that all of our patients had genotype D infection. 7 However, this may be also viewed as an advantage because the outcome of chronic genotype D HBV infection appears to be worse compared with genotype A, which is also encountered in Europe and similar to other HBV genotypes. 7 In conclusion, our study shows that effective 4- to 5-year treatment with ADV followed by drug discontinuation leads to HBsAg loss in approximately 40% of patients with well-compensated HBeAg-negative CHB. This is the highest rate of off-treatment HBsAg loss that has been achieved with any type of antiviral therapy in patients with chronic CHB so far. Supplementary Materials Note: To access the supplementary material accompanying this article, visit the online version of
8 636 HADZIYANNIS ET AL GASTROENTEROLOGY Vol. 143, No. 3 Gastroenterology at and at dx.doi.org/ /j.gastro References 1. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9: Hadziyannis SJ, apatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26: Manesis EK. HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol 2006;45: European Association for the Study of the Liver. EASL Clinical ractice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50: Liaw YF, Brunetto MR, Hadziyannis SJ. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010;15(Suppl 3): Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45: Hadziyannis SJ. Natural history of chronic hepatitis B in Euro- Mediterranean and African Countries. J Hepatol 2011;55: Hadziyannis SJ, Vassilopoulos D. Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antivir Res 2001;52: Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther 2011;16: Tassopoulos NC, Volpes R, astore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine recore Mutant Study Group. Hepatology 1999;29: Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-hbe/hbv DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32: Huang YH, Wu JC, Chang TT, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003;10: Fung SK, Wong F, Hussain M, et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigennegative chronic hepatitis B. J Viral Hepat 2004;11: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352: Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12: Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50: Liang Y, Jiang J, Su M, et al. redictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment harmacol Ther 2011;34: Liu F, Wang L, Li XY, et al. oor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011;26: Lok ASF, McMahon BJ. AASLD ractice Guidelines. Chronic hepatitis B: update Available at: Accessed September 12, Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2: Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121: Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009;50: Marcellin, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136: Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis b for up to 5 years. Gastroenterology 2006;131: Laras A, Koskinas J, Dimou E, et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006;44: Levrero M, ollicino T, etersen J, et al. Control of cccdna function in hepatitis B virus infection. J Hepatol 2009;51: apatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34: Received January 24, Accepted May 24, Reprint requests Address requests for reprints to: Stephanos J. Hadziyannis, MD, Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Mesogion Avenue, Athens 11526, Greece. hadziyannis@ath.forthnet.gr; fax: (30) Conflicts of interest The authors disclose no conflicts. Funding Sponsored in part by research grants from the Special Account for Research Grants, National and Kapodistrian University of Athens (Athens, Greece), and Gilead Sciences. The sponsors supported financially the performance of the laboratory tests for the first 2 years of the long-term follow-up observation and provided assistance in the statistical analysis of the results.
9 September 2012 SUSTAINED AND HBsAg LOSS IN CHB RESONSES 636.e1 A. B HBsAg (IU/L) HBsAg (IU/L) ALT (U/L) C. D E. F. ALT (U/L) HBV DNA (IU/mL) HBV DNA (IU/mL) Supplementary Figure 1. The time course of serial HBsAg, ALT, and HBV DNA titers during the posttreatment follow-up period in the 18 patients with SR who did not resume antiviral therapy are shown (A, C, and E, patients without HBsAg loss [n 5]; B, D, and F, patients with HBsAg loss [n 13]). The time interval for testing was every 3 months for the first 12 months and every 6 months (//) after month 12.
Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationNew therapeutic perspectives in HBV: when to stop NAs
Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,
More informationHepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Hepatol Int (2013) 7:88 97 DOI 10.1007/s12072-012-9343-x ORIGINAL ARTICLE Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationMedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article
HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationResponse-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationPros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
Curr Hepatitis Rep (2010) 9:91 98 DOI 10.1007/s11901-010-0041-7 Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B Milan J. Sonneveld & Harry L. A. Janssen
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationThe role of entecavir in the treatment of chronic hepatitis B
REVIEW The role of entecavir in the treatment of chronic hepatitis B Evangelini Dimou Vasilios Papadimitropoulos Stephanos J Hadziyannis Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens,
More informationAntiviral Therapy 2012; 17: (doi: /IMP1945)
Antiviral Therapy 2012; 17:387 394 (doi: 10.3851/IMP1945) Original article HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationDNA 2 91% (185/203), 82% (75/91), 75% (47/63), 62% (26/42) 200,000, 20, ,999, 2,000-19,999, <2,000 ( P
Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen Negative Chronic Hepatitis B Virus Infection? George V. Papatheodoridis, 1 Emanuel K. Manesis,
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationPredicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
699 HEPATITIS Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B F Bonino, P Marcellin, G K K Lau, S Hadziyannis, R Jin, T Piratvisuth, G
More informationOff-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
VIRAL HEPATITIS Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Wen-Juei Jeng, 1,2 I-Shyan Sheen, 1,2 Yi-Cheng Chen, 1,2 Chao-Wei
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationPredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
Title Author(s) Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Bonino, F; Marcellin, P; Lau, GKK; Hadziyannis, S; Jin, R; Piratvisuth,
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationThe importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B
The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B LIVER Kaan Demirören, Halil Kocamaz, Yaşar Doğan Department
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationPredicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
Gut Online First, published on November 24, 2006 as 10.1136/gut.2005.089722 1 Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Authors:
More informationTitle: Off therapy durability of response to Entecavir therapy in hepatitis B e
Title: Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients Wen-Juei Jeng, MD 1,3, I-Shyan Sheen, MD 1-3, Yi-Cheng Chen, MD 1,3, Chao-Wei
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationBeyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy
: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy Sunday, November 1, 2009 Back Bay Ballroom Sheraton Boston Hotel Boston, Massachusetts This program is supported by an educational
More informationChronic infection with the hepatitis B virus (HBV)
Adding-on Versus Switching-to Adefovir Therapy in Lamivudine-Resistant HBeAg-Negative Chronic Hepatitis B Irene Rapti, 1 Evangelini Dimou, 1,2 Panayota Mitsoula, 2 and Stephanos J. Hadziyannis 1,2 We studied
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationThe Journal of Infectious Diseases MAJOR ARTICLE
The Journal of Infectious Diseases MAJOR ARTICLE Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationCan Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?
DOI 10.1007/s11901-014-0236-4 HEPATITIS B (P MARTIN AND P LAMPERTICO, SECTION EDITORS) Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Stephanos J. Hadziyannis
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationChronic hepatitis B virus (HBV) infection remains a major
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
Accepted Manuscript A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update Paul Martin, MD, Daryl T.-Y. Lau, MD, MSc, MPH, Mindie H. Nguyen, MD,
More informationThe advent of sensitive assays for the detection of hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;-:1 10 All studies published in Clinical Gastroenterology and Hepatology are embargoed until 3PM ET of the day they are published as corrected proofs on-line.
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationFebruary 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:
February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance
More informationcoinfected patients predicts HBsAg clearance during long term exposure to tenofovir
Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationRelation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection
Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection xxxxxxxxxxxxxxx Özgür Günal 1, Şener Barut 1, İlker Etikan 2, Fazilet Duygu 1, Umut Tuncel 3, Mustafa
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationCurrently, hepatitis B e antigen (HBeAg)-negative hepatitis
GASTROENTEROLOGY 2010;139:483 490 Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers MAURIZIA ROSSANA BRUNETTO,* FILIPPO OLIVERI,* PIERO
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationChronic hepatitis B (CHB) is the leading cause of
GASTROENTEROLOGY 2013;144:933 944 CLINICAL LIVER Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment GRACE LAI HUNG WONG, 1,2 HENRY LIK YUEN CHAN, 1,2 HOI YUN CHAN,
More informationHBV (AASLD) CHB, HBV, CHB , ( < 5% ) 11 ( immune tolerant phase) : 21 ( immune clearance phase ) : 31 ( inactive phase) : HBeAg - HBe HBV DNA ALT
2010262 125 R51216 + 2 C 1001-5256 (2010) 02-0125 - 06 2005 12 [ 1 ], (HBV ) (APASL) ( EASL ) (AASLD) (CHB) [ 2 4 ], ( ) ( ), CHB,, CHB CHB,, CHB,, 2 1 HBV hepatitis B virus CHB chronic hepatitis B HB
More informationMin Weng, Wei-Zheng Zeng *, Xiao-Ling Wu, Yong Zhang, Ming-De Jiang, Zhao Wang, De-Jiang Zhou and Xuan He
Weng et al. Virology Journal 2013, 10:277 RESEARCH Open Access Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis
More informationTherapeutic Guidelines on Management of Chronic Hepatitis B in Asia
SPECIAL FEATURE Vol.6 No.2 (April 2001) Therapeutic Guidelines on Management of Chronic Hepatitis B in Asia Abstract Dr. Nancy Leung Department of Medicine and Therapeutics, Prince of Wales Hospital, The
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated Interferon alfa 2a, 180 mcg for subcutaneous injection (Pegasys ) No. (186/05) Roche New indication (chronic hepatitis B) 10 June 2005 The Scottish Medicines Consortium
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationDynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 183-188 CASE REPORT Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative
More informationChronic hepatitis B (CHB) infection is a large
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationChronic hepatitis B is one of the leading causes of hepatocellular. Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1113 1120 Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B VINCENT WAI SUN WONG,*, GRACE LAI HUNG WONG,*, ANGEL MEI LING CHIM,*,
More informationIndividualizing Treatment in the Patient With Chronic HBV Infection: When to Start, What to Use, and When to Stop CME
Individualizing Treatment in the Patient With Chronic HBV Infection: When to Start, What to Use, and When to Stop CME Chia C. Wang, MD, MS Anna S. F. Lok, MD Kris V. Kowdley, MD Supported by an independent
More informationwith cirrhosis should remain under HCC surveillance
Hepatology Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine
More information